Gene expression profile at single cell level of bone marrow cells in 5TGM1 multiple myeloma mouse model treated with CD24 CAR-T cells

Durable remissions following anti-B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell treatment of multiple myeloma (MM) are rare. Relapses occur when a small subset of MM tumor-initiating cells (TICs) survive treatment. MM cells expressing CD24 exhibit features of TICs. We developed CD24-CAR-T cells and tested their ability to eliminate MM TICs in vitro and in vivo. We analyzed the immune cell changes in the BM microenvironment of the 5TGM1 mouse model treated with CD24 CAR-T cells using single-cell RNA sequencing (scRNA-seq).